Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2016 07:00 ET | Source: Kyntra Bio

FibroGen to Report Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016

SAN FRANCISCO, Feb. 19, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...
February 16, 2016 07:20 ET | Source: Kyntra Bio

FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat’s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease

SAN FRANCISCO, Feb. 16, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today announced that the American Journal of Kidney Disease...
January 27, 2016 21:27 ET | Source: Kyntra Bio

FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer

SAN FRANCISCO, Jan. 27, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (FibroGen) today announced early results from a Phase 2, randomized, open-label study of FG-3019, an investigational anti-fibrotic...
January 06, 2016 17:46 ET | Source: Kyntra Bio

FibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular Dystrophy

SAN FRANCISCO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”) announced today enrollment of the first two patients in an open-label, multicenter Phase 2 clinical...
November 12, 2015 16:02 ET | Source: Kyntra Bio

FibroGen Announces Third Quarter 2015 Financial Results

SAN FRANCISCO, Nov. 12, 2015 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today reported financial results for the quarter ended...
November 05, 2015 16:05 ET | Source: Kyntra Bio

FibroGen to Report Third Quarter 2015 Financial Results on November 12, 2015

SAN FRANCISCO, Nov. 05, 2015 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel...
November 03, 2015 16:31 ET | Source: Kyntra Bio

FibroGen to Present Roxadustat Clinical Data in Four Presentations at American Society of Nephrology - Kidney Week 2015

SAN FRANCISCO, Nov. 03, 2015 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”), today announced that analyses of clinical data from Phase 2 clinical trials of roxadustat (FG‑4592), a...
October 29, 2015 19:27 ET | Source: Kyntra Bio

FibroGen Appoints Jeffrey Edwards to Board of Directors

SAN FRANCISCO, Oct. 29, 2015 (GLOBE NEWSWIRE) -- FibroGen, Inc. (“FibroGen”) (NASDAQ:FGEN), a research-based biopharmaceutical company, today announced that Jeffrey Edwards has been named to the...
October 22, 2015 19:14 ET | Source: Kyntra Bio

Phase 2 Data for Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Show Anemia Correction in Incident Dialysis Chronic Kidney Disease Patients Regardless of Iron Repletion Status, Iron Supplementation Regimen, or Dialysis Modality

SAN FRANCISCO, Oct. 22, 2015 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, along with its partner, AstraZeneca (NYSE:AZN), today...
August 13, 2015 16:01 ET | Source: Kyntra Bio

FibroGen Announces Second Quarter 2015 Financial Results

SAN FRANCISCO, Aug. 13, 2015 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) ("FibroGen"), a research-based biopharmaceutical company, today reported financial results for the quarter ended June 30,...